Yi-Bin Chen, MD; Nelson J. Chao, MD, MBA; Hannah Choe, MD; and Sophie Paczesny, MD, PhD, review updates in the diagnosis and treatment of graft-vs-host disease.
EP. 1: Overview of Graft-vs-Host Disease (GVHD)
Nelson J. Chao, MD, MBA, and Yi-Bin Chen, MD, define common signs and symptoms of GVHD and share insight on approaching the diagnosis of disease.
EP. 2: Challenges in Early Detection of GvHD
Hannah Choe, MD; Nelson J. Chao, MD, MBA; and Sophie Paczesny, MD, PhD, comment on the importance of early detection of disease and the role of biomarker testing in GVHD.
EP. 3: Selecting GVHD Prophylaxis
Nelson J. Chao, MD, MBA, reviews current GVHD prophylaxis options and factors to consider when selecting one for a given patient.
EP. 4: ASH 2021 Updates for GVHD Prophylaxis
Sophie Paczesny, MD, PhD; Yi-Bin Chen, MD; and Hannah Choe, MD, review recent advances in GVHD prophylaxis as presented at the 2021 American Society of Hematology (ASH) Annual Meeting and Symposium.
EP. 5: Impact of GVHD on Patient Outcomes
Yi-Bin Chen, MD, and Nelson J. Chao, MD, MBA, comment on the changing landscape of GVHD and the effect on patient outcomes.
EP. 6: Goals of Therapy for Acute GVHD Treatment
Hannah Choe, MD, discusses triggers to initiate acute GVHD therapy and goals of treatment.
EP. 7: Evolution of Treatment for Acute GVHD
Sophie Paczesny, MD, PhD, provides insight on how strategies to treat acute GVHD have changed over time regarding outcomes and pathophysiology of disease.
EP. 8: Overview of Steroid-Refractory Acute GVHD
Nelson J. Chao, MD, MBA, and Hannah Choe, MD, define steroid-refractory acute GVHD and current treatment options for the disease.
EP. 9: Steroids for First-Line Treatment of Chronic GVHD
Yi-Bin Chen, MD, leads a discussion on the use of steroids as first-line treatment of chronic GVHD and when to switch therapy.
EP. 10: Steroid-Refractory Chronic GVHD: Management Strategies
Hannah Choe, MD; Sophie Paczesny, MD, PhD; and Nelson J. Chao, MD, MBA, review the use of current FDA approved therapies—ruxolitinib, ibrutinib, and belumosudil—for the treatment of steroid-refractory chronic GVHD.
EP. 11: Treatment Selection for Steroid-Refractory GVHD
Hannah Choe, MD, leads the discussion on clinical experiences using off-label regimens to treat steroid-refractory chronic GVHD, and the optimal sequencing of therapy.
EP. 12: Future of Steroid-Refractory Chronic GVHD Treatment
Drs Hannah Choe, Yi-Bin Chen, Nelson J. Chao, and Sophie Paczesny explore emerging treatment options in the pipeline for the treatment of steroid-refractory chronic GVHD.
EP. 13: Clinical Manifestations of Chronic GVHD
Drs Hannah Choe, Nelson J. Chao, Sophie Paczesny, and Yi-Bin Chen share their approach to treating patients with chronic GVHD who present initially with either scleroderma or bronchiolitis obliterans.
EP. 14: Supportive Care for Steroid-Refractory Chronic GVHD Treatment
Hannah Choe, MD, leads a review of the role of supportive care and a multidisciplinary team approach to care for the treatment of steroid-refractory chronic GVHD.
EP. 15: Unmet Needs in GVHD Management
Drs Sophie Paczesny, Hannah Choe, Nelson J. Chao, and Yi-Bin Chen share unmet needs in GVHD and advice for disease management.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer